These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 28542350)
1. T0001, a variant of TNFR2-Fc fusion protein, exhibits improved Fc effector functions through increased binding to membrane-bound TNFα. Shen Y; Li G; Gu C; Chen B; Chen A; Li H; Gao B; Liang C; Wu J; Yang T; Jin L; Su Y PLoS One; 2017; 12(5):e0177891. PubMed ID: 28542350 [TBL] [Abstract][Full Text] [Related]
2. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Mitoma H; Horiuchi T; Tsukamoto H; Tamimoto Y; Kimoto Y; Uchino A; To K; Harashima S; Hatta N; Harada M Arthritis Rheum; 2008 May; 58(5):1248-57. PubMed ID: 18438840 [TBL] [Abstract][Full Text] [Related]
3. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Kaymakcalan Z; Sakorafas P; Bose S; Scesney S; Xiong L; Hanzatian DK; Salfeld J; Sasso EH Clin Immunol; 2009 May; 131(2):308-16. PubMed ID: 19188093 [TBL] [Abstract][Full Text] [Related]
4. Differences in binding and effector functions between classes of TNF antagonists. Arora T; Padaki R; Liu L; Hamburger AE; Ellison AR; Stevens SR; Louie JS; Kohno T Cytokine; 2009 Feb; 45(2):124-31. PubMed ID: 19128982 [TBL] [Abstract][Full Text] [Related]
5. Anti-Tumor Necrosis Factor With a Glyco-Engineered Fc-Region Has Increased Efficacy in Mice With Colitis. Bloemendaal FM; Levin AD; Wildenberg ME; Koelink PJ; McRae BL; Salfeld J; Lum J; van der Neut Kolfschoten M; Claassens JW; Visser R; Bentlage A; D'Haens GRAM; Verbeek JS; Vidarsson G; van den Brink GR Gastroenterology; 2017 Nov; 153(5):1351-1362.e4. PubMed ID: 28756234 [TBL] [Abstract][Full Text] [Related]
6. A Novel System for the Quantification of the ADCC Activity of Therapeutic Antibodies. Lallemand C; Liang F; Staub F; Simansour M; Vallette B; Huang L; Ferrando-Miguel R; Tovey MG J Immunol Res; 2017; 2017():3908289. PubMed ID: 29104875 [TBL] [Abstract][Full Text] [Related]
7. Anti-tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner. Vos AC; Wildenberg ME; Duijvestein M; Verhaar AP; van den Brink GR; Hommes DW Gastroenterology; 2011 Jan; 140(1):221-30. PubMed ID: 20955706 [TBL] [Abstract][Full Text] [Related]
8. Binding and functional comparisons of two types of tumor necrosis factor antagonists. Scallon B; Cai A; Solowski N; Rosenberg A; Song XY; Shealy D; Wagner C J Pharmacol Exp Ther; 2002 May; 301(2):418-26. PubMed ID: 11961039 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and immunogenicity of T0001, a newly developed anti-TNFα fusion protein, in healthy volunteers. Wang Y; Liu C; Chen S; Wang W; Dong L; Wang Q; Wang Y; Zhao L; Zang Y; Xie Z; Liu Y; Liu Y; Song H; Li Z; Fang Y Eur J Clin Pharmacol; 2017 Sep; 73(9):1095-1101. PubMed ID: 28639118 [TBL] [Abstract][Full Text] [Related]
10. Effects of Soluble Tumor Necrosis Factor (TNF) on Antibody-Dependent Cellular Cytotoxicity of Therapeutic anti-TNF-α Antibody. Hirosaki H; Maeda Y; Shimojima M; Maeda K; Iwata H; Takeyoshi M Immunol Invest; 2019 Jul; 48(5):441-450. PubMed ID: 30569777 [TBL] [Abstract][Full Text] [Related]
11. The pharmacology study of a new recombinant TNF receptor-hyFc fusion protein. Lee JH; Cho JH; Yeo J; Lee SH; Yang SH; Sung YC; Kang JH; Park CS Biologicals; 2013 Mar; 41(2):77-83. PubMed ID: 23190454 [TBL] [Abstract][Full Text] [Related]
15. Biochemical characterization of a new recombinant TNF receptor-hyFc fusion protein expressed in CHO cells. Lee JH; Yeo J; Park HS; Sung G; Lee SH; Yang SH; Sung YC; Kang JH; Park CS Protein Expr Purif; 2013 Jan; 87(1):17-26. PubMed ID: 23009882 [TBL] [Abstract][Full Text] [Related]
16. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies. Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226 [TBL] [Abstract][Full Text] [Related]
18. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody. Zhang D; Goldberg MV; Chiu ML J Biol Chem; 2016 Dec; 291(53):27134-27146. PubMed ID: 27856634 [TBL] [Abstract][Full Text] [Related]
19. Infliximab and the TNF-alpha system. Ebert EC Am J Physiol Gastrointest Liver Physiol; 2009 Mar; 296(3):G612-20. PubMed ID: 19136378 [TBL] [Abstract][Full Text] [Related]
20. TNF receptor II fusion protein with tandemly repeated Fc domains. Nagashima H; Kaneko K; Yamanoi A; Motoi S; Konakahara S; Kohroki J; Masuho Y J Biochem; 2011 Mar; 149(3):337-46. PubMed ID: 21278157 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]